黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery

Biomaterials. 2024-05; 
Maoyi Li, Nanhui Liu, Jiafei Zhu, Yumin Wu, Le Niu, Yi Liu, Linfu Chen, Boxiong Bai, Yu Miao, Yang Yang, Qian Chen
Products/Services Used Details Operation
Catalog Antibody After incubation, the PVDF membrane underwent five washes with TBST before being exposed to an HRP-conjugated anti-rabbit secondary antibody (A01827, GenScript Biotech, diluted to a ratio of 1:5000). Get A Quote

摘要

Inflammatory bowel disease (IBD) is a kind of auto-immune disease characterized by disrupted intestinal barrier and mucosal epithelium, imbalanced gut microbiome and deregulated immune responses. Therefore, the restoration of immune equilibrium and gut microbiota could potentially serve as a hopeful approach for treating IBD. Herein, the oral probiotic Escherichia coli Nissle 1917 (ECN) was genetically engineered to express secretable interleukin-2 (IL-2), a kind of immunomodulatory agent, for the treatment of IBD. In our design, probiotic itself has the ability to regulate the gut microenvironment and IL-2 at low dose could selectively promote the generation of regulatory T cells to elicit tolerogenic immune r... More

关键词